IMInes De Mesmaeker

Ines De Mesmaeker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ines De Mesmaeker has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Function and composition of pancreatic islet cell implants in omentum of type 1 diabetes patients

    by Freya Van Hulle, Kaat De Groot, Robert Hilbrands, Ursule Van de Velde, Krista Suenens, Geert Stangé, Ines De Mesmaeker, Diedert L. De Paep, Zhidong Ling, Bart Roep, et al.


  • Open Access

    Formation of amyloid in encapsulated human pancreatic and human stem cell-generated beta cell implants

    by Freya Van Hulle, Kaat De Groot, Geert Stangé, Krista Suenens, Ines De Mesmaeker, Diedert L. De Paep, Zhidong Ling, Robert Hilbrands, Pieter Gillard, Bart Keymeulen, et al.


  • Open Access

    Cell Mass Increase Associated with Formation of Glucose-Controlling β-Cell Mass in Device-Encapsulated Implants of hiPS-Derived Pancreatic Endoderm

    by Thomas Robert, Ines De Mesmaeker, Freya O. Van Hulle, Krista G. Suenens, Geert M. Stangé, Zhidong Ling, Corinne Haller, Nicolas Bouche, Bart Keymeulen, Marine R.C. Kraus, et al.

    Device-encapsulated human stem cell-derived pancreatic endoderm (PE) can generate functional β-cell implants in the subcutis of mice, which has led to the start of clinical studies in type 1 diabetes. Assessment of the formed functional β-cell mass (FBM) and its correlation with in vivo metabolic markers can guide clinical translation. We recently reported ex vivo characteristics of device-encapsulated human embryonic stem cell-derived (hES)-PE implants in mice that had established a metabolically adequate FBM during 50-week follow-up. Cell suspensions from retrieved implants indicated a correlation with the number of formed β cells and their maturation to a functional state comparable to human pancreatic β cells. Variability in metabolic outcome was attributed to differences in number of PE-generated β cells. This variability hinders studies on processes involved in FBM-formation. This study reports modifications that reduce variability. It is undertaken with device-encapsulated human induced pluripotent stem cell-derived-PE subcutaneously implanted in mice. Cell mass of each cell type was determined on intact tissue inside the device to obtain more precise data than following isolation and dispersion. Implants in a preformed pouch generated a glucose-controlling β-cell mass within 20 weeks in over 60% of recipients versus less than 20% in the absence of a pouch, whether the same or threefold higher cell dose had been inserted. In situ analysis of implants indicated a role for pancreatic progenitor cell expansion and endocrine differentiation in achieving the size of β- and α-cell mass that correlated with in vivo markers of metabolic control. Stem Cells Translational Medicine 2019;8:1296&1305


  • Increase Functional β-Cell Mass in Subcutaneous Alginate Capsules With Porcine Prenatal Islet Cells but Loss With Human Adult Islet Cells

    by Ines De Mesmaeker, Thomas Robert, Krista G. Suenens, Geert M. Stangé, Freya Van Hulle, Zhidong Ling, Peter Tomme, Daniel Jacobs-Tulleneers-Thevissen, Bart Keymeulen, Daniel G. Pipeleers

    Alginate-encapsulated porcine islet cell grafts are developed to overcome limitations of human islet transplantation. They can generate functional implants in animals when prepared from fetal, perinatal and adult pancreases. Implants have not yet been examined for efficacy to establish sustained metabolically-adequate functional beta cell mass (FBM) with comparison to human islet cells. This study in immune-compromised mice demonstrates that subcutaneous implants of Alg-porcine-prenatal islet cells with 4x105 beta cells form, over 10 weeks, a FBM that results in glucose-induced plasma C-peptide >2 ng/mL and metabolic control over the following 10 weeks, with higher efficiency than non-encapsulated, while failing in peritoneum. This intracapsular FBM-formation involves beta cell replication, increasing number 4-fold, and maturation towards human adult beta cells. Subcutaneous Alg-human islet cells with similar beta cell number establish implants with plasma C-peptide >2 ng/mL for the first 10 weeks, while failing non-encapsulated; their beta cells do not replicate but progressively die (>70%) explaining C-peptide decline and insufficient metabolic control. An alginate matrix thus helps establish beta cell functions in subcutis. It allows formation of sustained metabolically-adequate FBM by immature porcine beta cells with proliferative activity but not by human adult islet cells. These findings define conditions for evaluating its immune-protecting properties.


  • Open Access

    Functional Beta Cell Mass from Device-Encapsulated hESC-Derived Pancreatic Endoderm Achieving Metabolic Control

    by Thomas Robert, Ines De Mesmaeker, Geert M. Stangé, Krista G. Suenens, Zhidong Ling, Evert J. Kroon, Daniel G. Pipeleers


  • Open Access

    Heterogeneity in the Beta-Cell Population: a Guided Search Into Its Significance in Pancreas and in Implants

    by Daniel Pipeleers, Ines De Mesmaeker, Thomas Robert, Freya Van Hulle

    Purpose of Review Intercellular differences in function have since long been noticed in the pancreatic beta-cell population. Heterogeneity in cellular glucose responsiveness is considered of physiological and pathological relevance. The present review updates evidence for the physiologic significance of beta-cell heterogeneity in the pancreas. It also briefly discusses what this role would imply for beta-cell implants in diabetes. Recent Findings Over the past 3 years, functionally different beta cells have been related to mechanisms that may underlie their heterogeneity in the pancreas, such as the stage in their life cycle and the degree of their clustering to islets with varying vascularization. Markers were identified for detecting these subpopulations in tissues. Summary The existence of a functional heterogeneity in the pancreatic beta-cell population is further supported. Views on its origin and methods for its analysis in pancreas and implants will help guide the search into its significance in beta-cell biology, pathology, and therapy.


  • Open Access

    Concise Review: Markers for Assessing Human Stem Cell-Derived Implants as β-Cell Replacement in Type 1 Diabetes

    by Daniel Pipeleers, Thomas Robert, Ines De Mesmaeker, Zhidong Ling

    A depleted β-cell mass causes diabetes complications that cannot be avoided by insulin administration. β-Cell replacement can stop their development when restoring insulin's homeostatic role. This requires a sufficient number and an adequate functional state of the β cells, together defined as “functional β-cell mass.” Intraportal implants of human pancreatic islet cells correct hyperglycemia in patients with type 1 diabetes, but this effect is transient and often incomplete. Studies to improve outcome are hindered by shortage in donor pancreases. Human pluripotent stem cells are a candidate source for mass production of grafts for β-cell replacement. Their in vitro differentiation to pancreatic endoderm (stage 4) and to β-cell-containing preparations (stage 7) provides grafts that generate β-cell implants in mice. In vivo markers indicated a better outcome of device-encapsulated stage 4 cells and microencapsulated stage 7 cells as compared with nonencapsulated grafts. Encapsulation also offers the advantage of representative implant retrieval for direct analysis by ex vivo markers. Combination of in vitro, in vivo, and ex vivo markers allows comparison of different stem cell-derived grafts and implants, with each other and with clinical islet cell preparations that serve as reference. Data in mice provide insights into the biology of stem cell-generated β-cell implants, in particular their capacity to establish and sustain a functional β-cell mass. They can thus be indicative for translation of a graft to similar studies in patients, where metabolic benefit will be an additional marker of primordial importance. Significance: Human stem cell-derived preparations can generate insulin-producing implants in immune-incompetent mice. Steps are undertaken for translation to patients with type 1 diabetes. Their therapeutic significance will depend on their capacity to establish a functional β-cell mass that provides metabolic benefit. This study proposes the combined use of in vitro, in vivo, and ex vivo markers to assess this potential in preclinical models and in clinical studies.